TELA Bio Short Interest Surges 19.6% in March

Shares of the medical technology company drop as short bets increase

Apr. 17, 2026 at 6:23pm

Got story updates? Submit your updates here. ›

A close-up macro photograph of the internal mechanical components of a medical device, such as gears, sensors, or electronic circuits, in a dark, industrial style. The image conveys a sense of the complex engineering and technology behind TELA Bio's regenerative medicine products.As short bets on TELA Bio increase, the intricate engineering behind the company's regenerative medicine solutions comes into focus.Malvern Today

TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on regenerative medicine and soft tissue repair solutions, saw a significant 19.6% increase in short interest during March. As of March 31st, there were 690,940 shares sold short, up from 577,693 shares on March 15th. This represents 1.6% of the company's total shares outstanding.

Why it matters

The rise in short interest suggests investors are increasingly bearish on TELA Bio's prospects, potentially due to concerns over the company's financial performance or competitive landscape. Elevated short interest can put downward pressure on a stock's price and signal broader market skepticism about a company's outlook.

The details

TELA Bio's short interest ratio, which measures the number of shares sold short relative to the stock's average daily trading volume, increased to 2.9 days as of March 31st. This indicates it would take nearly 3 days for short sellers to cover their positions based on typical volume. The company's shares closed at $0.68 on Friday, down $0.05 on the day, as the stock continues to trade well below its 52-week high of $2.20.

  • As of March 31st, TELA Bio had 690,940 shares sold short.
  • On March 15th, the short interest was 577,693 shares.

The players

TELA Bio, Inc.

A commercial-stage medical technology company focused on regenerative medicine and advanced soft tissue repair solutions.

Got photos? Submit your photos here. ›

The takeaway

The surge in short interest for TELA Bio suggests growing investor skepticism about the company's near-term prospects, which could put further downward pressure on the stock price. However, the company's long-term potential in the regenerative medicine space remains to be seen as it continues to develop and commercialize its portfolio of innovative products.